GINKGO BIOWORKS HOLDINGS INC

DNANYSE

🏆 #2602 by market capEarnings Nov 5US Equity

$7.32▼ $0.19 (−2.53%)

Live

1h▲ 0.5%

24h▼ 2.5%

7d▼ 22.0%

14d▼ 3.8%

30d▼ 19.2%

1y▼ 36.3%

🏦Market Cap

$456M

Small Cap

📈Revenue Growth (YoY)

-40.5%

Declining

📊Gross Margin

73.1%

High

💵FCF Margin

—

⚖️P/S Ratio

3.6x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $7.27 – $7.44
52-Week Range: $5.37 – $17.58
Volume: $5.31B
Avg Volume: $5.00B
Shares Outstanding: 62.3M
Next Earnings: Oct 22, 2026

Fundamentals Snapshot

Annual Revenue: $170M
Last Q Revenue: $20M
P/E Ratio: —
P/S Ratio: 3.6x
EPS (TTM): $-5.35
Dividend Yield: —

Why Investors Own DNA

✓High-growth profile — revenue up +39.7% YoY with expanding US Equity exposure.
✓Healthy economics — 35% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$170M▲ +41.8% YoY

Gross Margin (TTM)

34.8%▲ +2.3% YoY

Operating Income (TTM)

$47M▲ +41.8% YoY

Free Cash Flow (TTM)

$26M▲ +41.8% YoY

About GINKGO BIOWORKS HOLDINGS INC

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

🦦